- Home
- NEN vs CERS Comparison
NEN vs CERS Comparison
Compare NEN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- CERS
- Stock Information
- Founded
- NEN 1977
- CERS 1991
- Country
- NEN United States
- CERS United States
- Employees
- NEN N/A
- CERS N/A
- Industry
- NEN Building operators
- CERS EDP Services
- Sector
- NEN Real Estate
- CERS Technology
- Exchange
- NEN Nasdaq
- CERS Nasdaq
- Market Cap
- NEN 250.0M
- CERS 276.0M
- IPO Year
- NEN N/A
- CERS 1997
- Fundamental
- Price
- NEN $71.06
- CERS $1.45
- Analyst Decision
- NEN
- CERS Buy
- Analyst Count
- NEN 0
- CERS 1
- Target Price
- NEN N/A
- CERS $4.00
- AVG Volume (30 Days)
- NEN 1.4K
- CERS 1.1M
- Earning Date
- NEN 01-01-0001
- CERS 11-06-2025
- Dividend Yield
- NEN 6.75%
- CERS N/A
- EPS Growth
- NEN 34.86
- CERS N/A
- EPS
- NEN 4.59
- CERS N/A
- Revenue
- NEN $83,884,808.00
- CERS $192,510,000.00
- Revenue This Year
- NEN N/A
- CERS $19.07
- Revenue Next Year
- NEN N/A
- CERS $12.03
- P/E Ratio
- NEN $15.36
- CERS N/A
- Revenue Growth
- NEN 4.96
- CERS 13.25
- 52 Week Low
- NEN $68.41
- CERS $1.12
- 52 Week High
- NEN $84.00
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- NEN 48.31
- CERS 46.04
- Support Level
- NEN $69.08
- CERS $1.48
- Resistance Level
- NEN $71.00
- CERS $1.54
- Average True Range (ATR)
- NEN 0.59
- CERS 0.08
- MACD
- NEN -0.03
- CERS -0.02
- Stochastic Oscillator
- NEN 67.86
- CERS 17.86
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.